1. Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. (13th April 2020) Authors: Gisondi, P.; Virga, C.; Piaserico, S.; Meneguzzo, A.; Odorici, G.; Conti, A.; Girolomoni, G. Journal: British journal of dermatology Issue: Volume 183:Number 2(2020) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. (1st August 2020) Authors: Gisondi, P.; Virga, C.; Piaserico, S.; Meneguzzo, A.; Odorici, G.; Conti, A.; Girolomoni, G. Journal: British journal of dermatology Issue: Volume 183:Number 2(2020) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗